A drug candidate critical to Takeda's mainstay diabetes franchise is expected to show sufficient promise to gain approval but may not be much better than Januvia, a rival medicine from Merck.
Takeda's drug, called alogliptin or SYR-322, is under regulatory review and data will be presented at the American Diabetes Association's annual meeting, which runs from June 6-10.
More at Reuters
1 comment:
Januvia is causing severe joint pain in many consumers, a side effect reported in 2006 that has disappeared from Merck prescribing information. Shades of Vioxx?
Post a Comment